New IndiPHARM initiative aims to revolutionize personalized medication management

A Columbia University-led multicenter research effort called IndiPHARM: individual metabolome and exposome assessment for pharmaceutical optimization will develop a platform and monitoring system to prevent unwanted interactions between medications and other environmental, genetic, and lifestyle factors, in order to optimize therapeutic efficacy.

FDA-approved drug may help to decrease pain after surgery, study finds

Researchers in the Department of Anesthesia and Perioperative Medicine at the Medical University of South Carolina (MUSC) have found that an FDA-approved drug may help

January 13, 2024

Inari updates label of clot removal device linked to 6 deaths

Dive Brief: Inari Medical has recalled a device for removing clots and blockages from large blood vessels outside the heart, the Food and Drug Administration

August 27, 2024

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous 01.10.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed

October 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.